口服重组抗人乳头瘤病毒疫苗(RHPV 16 & 18)的非临床安全性评价:小鼠、大鼠和兔的监管毒理学研究——一种创新方法
该研究评估了表达HPV 16和18型主要衣壳蛋白L1的重组伤寒沙门菌Ty21a(rStHPV)的非临床安全性。在小鼠和大鼠中经鼻内单次给予临床预防剂量的10倍和50倍进行急性毒性试验,在大鼠和兔中经口服和鼻内途径给予预防剂量及平均5倍临床剂量进行亚慢性毒性试验。结果显示即使更高剂量下也未见可观察的不良反应,且鼻内途径可诱导显著的抗HPV IgG应答。
要点
- rStHPV在高达临床剂量50倍时未显示可观察的不良反应。
- 鼻内途径给予rStHPV可显著增加抗HPV特异性IgG水平。
- 研究采用鼻内途径进行非临床毒理学评价,为监管指南之外的替代途径。
核心结论
- 研究结果表明rStHPV即使在高于预期临床剂量(5、10和50倍)时也无可观察的不良反应。
- 抗HPV特异性IgG显著增加表明疫苗具有免疫原性。
研究设计与样本
- 急性毒性:小鼠和大鼠经鼻内单次给予临床预防剂量的10倍和50倍,监测生存14天。
- 亚慢性毒性:大鼠和兔经口服和鼻内途径,在第1、3、5天给予预防剂量及平均5倍临床剂量。
- 免疫/过敏反应:小鼠经鼻内和腹腔途径评估。
- 实验动物每日监测活体阶段,并在第15、29和93天进行临床化学、血液学、免疫毒理学、免疫原性反应和重要器官的组织病理学检查。
主要发现
- 活体阶段活动、临床化学和血液学特征未见异常变化。
- 大体剖检、器官重量和组织病理学均正常。
- 通过I级试验评估未记录到免疫毒性。
- 无论测试途径如何,以IgE水平评估的过敏免疫反应均为阴性。
- 鼻内途径暴露的小鼠抗HPV IgG水平显著增加(P < 0.01)。
关键数值与推荐
- 急性毒性剂量为临床预防剂量的10倍和50倍(小鼠和大鼠,鼻内单次)。
- 亚慢性毒性剂量为预防剂量及平均5倍临床剂量(大鼠和兔,口服和鼻内,第1、3、5天)。
- 抗HPV IgG显著增加(P < 0.01,鼻内途径小鼠)。
- 终末前死亡率:小鼠6-15%,大鼠10%,兔15%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The human papilloma virus (HPV) type 16 and 18 causes nearly 70% of uterine cervical cancers. Oral administration of live Salmonella typhi Ty21a, expressing major capsid proteins (L1) of HPV 16 and 18 is a potential choice for immunization in adolescent girls under low resource settings. Present study aimed to assess the nonclinical safety of recombinant S. typhi expressing HPV 16 and 18 (rStHPV) proteins. METHODOLOGY: The acute toxicity of rStHPV was tested by intranasal single dose administration, of 10 and 50 folds higher than clinical prophylactic dose, in mice and rat followed by monitoring their survival for 14 days. Sub-chronic toxicity was evaluated in rats and rabbits with prophylactic and 5 times (average) to clinical prophylactic dosages on scheduled days (1st, 3rd & 5th day) through oral and intranasal routes. The immune/allergic response of rStHPV was assessed in mice through intranasal and intra-peritoneal routes. Experimental animals were daily monitored for live phase, and clinical chemistry, haematology, immunotoxicology, immunogenic response and histopathological examination of vital organs on 15th, 29th and 93rd days. RESULTS: No abnormal changes were noticed in live phase activity, clinical chemistry and haematology profile. The gross necropsy, organ weights and histopathology were found to be normal. No immunotoxicity was recorded as evaluated by tier I tests. Allergic immune response, as evaluated with IgE levels was also negative irrespective of test routes. On the other hand, a significant (P < 0.01) increase of anti-HPV IgG levels was noted in mice exposed through intranasal route. Though the pre-terminal mortality was noted in mice (6-15%), rats (10%) and rabbits (15%), the autopsy revealed no signs of toxicity related to rStHPV, as the changes neither significant nor dose dependent; and even noted in vehicle control also. CONCLUSION: The study results suggested 'no observable adverse effects' of rStHPV even at higher dosages (5, 10 & 50 folds) than intended clinical dose. A significant increase of anti-HPV specific IgG suggests the immunogenicity of vaccine. The innovative approach of current study is nonclinical toxicology evaluation of vaccine through intra-nasal route, an alternate route apart from stipulated regulatory guidelines.
引用
- Srinivasa Reddy Y, Narendra Babu K, Uday Kumar P, et al. Nonclinical safety evaluation of oral recombinant anti-human papilloma virus vaccine (RHPV 16 & 18): Regulatory toxicology studies in mice, rats and rabbits - An innovative approach. Vaccine. 2020. PMID: 33388175. doi:10.1016/j.vaccine.2020.11.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。